Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price ...

Eli Lilly (LLY) closed the most recent trading day at $770.64, moving +1.04% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.96%. Meanwhile ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I initiate a Buy rating on LLY stock.

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes ...

Eli Lilly (LLY) closed the most recent trading day at $770.64, moving +1.04% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.96%. Meanwhile ...

Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds.As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at ...

A high-level overview of Eli Lilly and Company (LLY) stock. View (LLY) real-time stock price, chart, news, analysis, analyst reviews and more.

The Zacks Consensus Estimate for LLY’s 2025 sales and EPS implies a year-over-year increase of 33.03% and 68.9%, respectively. EPS estimates for 2025 and 2026 have declined over the past 60 days.

Currently trading with a volume of 1,003,032, the LLY's price is down by -3.48%, now at $757.73. RSI readings suggest the stock is currently may be approaching overbought.

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients ...